Unveiling SDCs Revolutionary BYOD ePRO Solution: A Landmark in Clinical Trials
Statistics & Data Corporation (SDC), a pioneer in clinical trial biometrics, has unveiled its groundbreaking Bring Your Own Device...
Jon Napitupulu
Merck’s Bomedemstat Begins Phase 3 Trial for Essential Thrombocythemia
Merck has launched Shorespan-007, a Phase 3 clinical trial evaluating bomedemstat for treating patients with essential thrombocythemia (ET) who...
Care Access Enters into New Partnership with BARDA to Sharpen Pandemic Preparedness
Care Access, a global health research company, has partnered with the Biomedical Advanced Research and Development Authority (BARDA) to...
Bristol Myers Squibb: Remarkable Data at European Cardiology Congress 2024
Bristol Myers Squibb (NYSE: BMY) showcased its robust cardiovascular franchise at the European Society of Cardiology (ESC) Congress in...
Announcing Areti Health’s Monumental Seed Round
Areti Health, a clinical trial recruitment innovator, has secured Preface Ventures and Almaz Capital funding. This investment will support...
Inverna INV724 Antibody Receives Rare Pediatric Disease and Orphan Drug Designations for Neuroblastoma Treatment
Invenra Inc.’s bispecific antibody, INV724, has received Rare Pediatric Disease (RPDD) and Orphan Drug (ODD) Designations from the FDA....
Rafael Holdings and Cyclo Therapeutics Seal Definitive Merger Pact
Rafael Holdings and Cyclo Therapeutics announce their merger to advance the development of Trappsol® Cyclo™ for treating Niemann-Pick Disease...
Catawba Research Unveils New Scientific Advisory Board
Catawba Research, striving to be a leading Contract Research Organization, announced the expansion of its Scientific Advisory Board with...
FDA Approves Pfizer BioNTech COVID KP.2 Omicron Vaccine: A Health Milestone
The U.S. Food and Drug Administration (FDA) has approved Pfizer and BioNTech‘s Omicron KP.2-adapted 2024-2025 Formula COVID-19 vaccine for...
Bayer Phase II Study of Revolutionary New Heart Drug in CKD Patients
Bayer has initiated the ALPINE-1 Phase II clinical trial to investigate BAY3283142, a soluble guanylate cyclase (sGC) activator, as...